Bio Search Signs Share-Exchange Deal for Brain-AI Firm InnerEye

Japan’s Bio Search announced on November 9, 2026 that it had signed a share-exchange agreement to acquire 100% of InnerEye, an Israeli company developing AI that analyzes brain signals in real time. The transaction would make InnerEye a wholly owned subsidiary and add its expert-decision technology to Bio Search’s healthcare AI business.

Completion has not yet occurred. Closing remains subject to customary conditions, including approvals from relevant Israeli authorities, and is scheduled between December 2026 and early January 2027.

InnerEye’s Expert-Mentoring Technology

InnerEye’s product documentation describes Minded A.I., its workflow for transferring aspects of expert judgment into AI models. An expert wears a device that serves as the interface, while the system converts elements of that person’s decisions into digital insights. Those insights teach models to reproduce expert decision patterns and also support assessments of user performance and trust in the expert’s decisions.

A continuing feedback loop is intended to improve both the models and their expert users. Sense.I applies this mentoring process to AI training, personalization and optimization. SensePlus focuses on the cognitive and emotional factors behind actions, with functions that include detecting fatigue as well as concentration and attention levels during tasks to help reduce human error.

Bio Search says InnerEye’s proprietary algorithms interpret electroencephalogram (EEG) readings in real time to distinguish cognitive states involved in perception and decision-making. Established in 2014, InnerEye was founded by Amir Geva, a professor of electrical and computer engineering at Ben-Gurion University of the Negev, and Leon Deouell, a physician and professor of brain sciences at the Hebrew University of Jerusalem. Their combined research underpins technology designed to learn decision processes rooted in personal experience and tacit knowledge before deploying the trained models.

Bio Search’s Integration Plan

For Bio Search, the acquisition adds real-time brain-signal algorithms to a business already using EEG, electrocardiogram (ECG), heart-rate and electromyography (EMG) signals in healthcare AI. Its existing operations span biological sensing, medical-device engineering and business development in Japan and other Asian markets. Pairing those capabilities with InnerEye’s software would connect signal capture and device design with models of expert judgment.

At the center of the integration plan is a shared platform for pooling both companies’ EEG and other biological data to train AI models. Bio Search projects improvements in precision, robustness and analytical scope, without quantifying the expected gains. Target uses include visualizing cognitive function, supporting early diagnosis, industrial automation, affective computing, security and decision support for experts.

InnerEye CEO Uri Antman described the combination as “the ideal partnership to elevate the Brain-AI technology we have cultivated over many years into a global commercial scale.” Beyond the technical integration, the companies plan a unified executive structure across Japan and Israel and stronger governance and internal controls. Bio Search has also set a target of a Nasdaq listing in 2028 as part of its expansion roadmap.

Regulatory approval and closing are the immediate requirements. The longer-term question is whether pooling brain and other biological data can produce models reliable enough for the broad healthcare and industrial uses Bio Search has identified, giving the 2028 listing target a concrete operational test.